Physician profile
James M Brown
NPI 1730159807
$6,144.70
in general payments reported to CMS, 2019-2025
38 companies · $2,714 in 2025
The $2,714 reported for 2025 was more than what 95% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $634 · 2020: $380 · 2021: $585 · 2022: $555 · 2023: $831 · 2024: $445 · 2025: $2,714.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,299 · Travel and Lodging: $1,692.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,298.95 |
| Travel and Lodging | $1,691.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coloplast Corp | $2,023.61 | 2021-2025 | Altis |
| Abbvie INC. | $759.59 | 2019-2025 | Lo Loestrin Fe, Orilissa, Ubrelvy |
| Pfizer INC. | $448.90 | 2019-2025 | |
| Amag Pharmaceuticals, INC. | $222.65 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $199.07 | 2019-2024 | Trintellix |
| Astellas Pharma US INC | $171.92 | 2022-2025 | Veozah |
| Mayne Pharma Commercial LLC | $169.15 | 2021-2025 | |
| Amgen INC. | $164.41 | 2019-2025 | Tezspire, Evenity, Prolia |
| Evofem Biosciences, INC. | $153.63 | 2021-2025 | Phexxi, Solosec, Phexx |
| Millicent US INC | $133.83 | 2020-2025 | Intrarosa, Femlyv, Femring |
| Allergan, INC. | $133.34 | 2020 | |
| Exeltis, USA INC. | $129.99 | 2019-2025 | Slynd |
| Dexcom, INC. | $126.04 | 2021-2025 | Dexcom G6 Transmitter |
| Novo Nordisk INC | $124.84 | 2024 | Wegovy |
| Sumitomo Pharma America, INC. | $122.59 | 2024-2025 | Myfembree, Gemtesa |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.